A Selective Adenosine A<sub>3</sub> Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models.

Kim, Yunhee; Kim, Dong Min; Son, Woo Chan; Moon, Byoung-Gon

A Selective Adenosine A₃ Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models.

Kim, Yunhee; Kim, Dong Min; Son, Woo Chan; Moon, Byoung-Gon.

Afiliação

Kim Y; Handok Inc., Seoul, Republic of Korea.
Kim DM; Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Son WC; Handok Inc., Seoul, Republic of Korea.
Moon BG; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea wcson@amc.seoul.kr byounggon.moon@handok.com.

In Vivo ; 36(5): 2186-2193, 2022.

Article em En | MEDLINE | ID: mdl-36099145

Assuntos

Nefropatias; Cirrose Hepática; Adenosina/farmacologia; Animais; Fibrose; Humanos; Cirrose Hepática/tratamento farmacológico; Cirrose Hepática/metabolismo; Camundongos; Antagonistas de Receptores Purinérgicos P1/uso terapêutico; Fator de Crescimento Transformador beta1/metabolismo

Palavras-chave

A3 AR antagonist; HL3501; liver fibrosis; preclinical model; renal fibrosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nefropatias / Cirrose Hepática Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nefropatias / Cirrose Hepática Idioma: En Ano de publicação: 2022 Tipo de documento: Article